How to Form a
New Jersey Corporation

New Jersey charges $125 to file a Certificate of Incorporation with the Division of Revenue and Enterprise Services (DORES) via business.nj.gov under N.J.S.A. 14A:2-7. No scaling based on authorized shares (unlike Delaware, Massachusetts, Michigan, Virginia). Expedited processing available: $50 for 8.5-hour same-day review, $500 for 2-hour, $1,000 for 1-hour under N.J.A.C. 17:3-1.1. Annual Report $78 due last day of anniversary month. Minimum Corporation Business Tax $500–$2,000 sliding scale under N.J.S.A. 54:10A-5(f) based on NJ gross receipts — even dormant NJ corps pay at least $500/yr. Eleet AI charges $299 all-in — $174 service + $125 state fee + registered agent for year one + filed Certificate delivered to your portal.

New Jersey's BASE Corporation Business Tax is graduated under N.J.S.A. 54:10A-5: 6.5% on first $50K of allocated net income, 7.5% on $50K–$100K, 9% above $100K. On top of that, the 2.5% CBT SURTAX (originally enacted P.L. 2018, c. 48 as a temporary measure) was RETROACTIVELY EXTENDED under P.L. 2023, c. 96 (signed June 30, 2023) through the end of tax year 2023. Then P.L. 2024, c. 22 (the "Corporate Transit Fee Act," signed June 28, 2024 by Gov. Murphy) imposed a NEW 2.5% Corporate Transit Fee on NJ-allocated net income ABOVE $10 MILLION retroactive to tax years beginning on or after Jan 1, 2024 through Dec 31, 2028, with revenue dedicated to NJ Transit. Combined effective rate for C-Corps with >$10M allocated net income: 11.5% (9% base + 2.5% CTF) — HIGHEST NOMINAL STATE CORPORATE TAX RATE IN THE UNITED STATES, exceeding Minnesota 9.8%, Illinois 9.5%, Pennsylvania 8.99%, Massachusetts 8%, California 8.84%. C-Corps below the $10M threshold pay the 9% base rate only. Planning implication: the same $15M of allocated net income costs $1,350,000 in MI (6% flat) vs $1,725,000 in NJ (11.5%) — a $375K annual tax delta that cannot be ignored in domicile decisions.

Yes. Under N.J.S.A. 54:10A-5(f), every NJ-registered corporation pays a MINIMUM Corporation Business Tax regardless of net income, sliding with NJ gross receipts: $500 for ≤$100K NJ gross receipts, $750 for $100K–$250K, $1,000 for $250K–$500K, $1,500 for $500K–$1M, $2,000 for >$1M. This is SEPARATE from the $78 Annual Report filing fee. A dormant NJ-domiciled holding company with zero income still owes $500/year in minimum CBT plus $78 Annual Report = $578/year baseline carrying cost. Compare to Delaware (minimum franchise tax for non-operating corp is $175/year plus $50 annual report = $225/year), Wyoming ($60/year license tax for ≤$1 in assets), Nevada (nominal annual list fee $150 + business license fee $500 = $650/year — actually comparable to NJ for minimum-case, but no corporate income tax on top), New Mexico ($0 annual report fee). For holding-company structures, NJ is one of the highest-carrying-cost jurisdictions in the US. For operating corps with substantial NJ income, the minimum is dwarfed by the actual CBT liability.

This is the standard Fortune 500 pharma playbook. Johnson & Johnson (HQ New Brunswick NJ since 1886) is incorporated in New Jersey — one of the few major pharma that stayed NJ-domiciled. Merck & Co (HQ Rahway NJ) is incorporated in New Jersey. Bristol-Myers Squibb (HQ Princeton NJ since 2009 Celgene-era relocation) is incorporated in Delaware. Bayer US (Whippany NJ — German parent Bayer AG), Sanofi US (Bridgewater NJ — French parent), Novartis Pharmaceuticals (East Hanover — Swiss parent Novartis AG): all foreign-parented, US subsidiaries structured under Delaware holding companies. The pattern: legacy NJ-incorporated pharma (J&J 1886, Merck 1891) remained in NJ because re-domestication has tax + shareholder-vote + contractual friction costs exceeding benefits. Newer or restructured pharma (BMS post-Celgene 2019, Organon post-Merck spinoff 2021 — incorporated in Jersey but parent Organon & Co. is Delaware) default to Delaware for M&A flexibility, institutional investor preference, and well-developed DGCL case law. Operating in NJ does NOT require NJ incorporation — foreign-qualification under N.J.S.A. 14A:13-1 costs $125 + the same $78 annual report + $500 minimum CBT as domestic NJ corps. For most new corps, Delaware + NJ foreign-qualification is the right answer if you'll have substantial NJ operations AND anticipate institutional investment or potential M&A exit.

N.J.S.A. 14A:12-7 is one of the most plaintiff-friendly shareholder oppression statutes in the United States, rivaling only Michigan's MCL § 450.1489. A minority shareholder in a closely-held NJ corporation may petition the Chancery Division of Superior Court for involuntary dissolution or (more commonly) fair-value buy-out when: (a) the directors are deadlocked in the management of corporate affairs AND the shareholders are unable to break the deadlock, or (b) the directors, officers, or those in control of the corporation have acted, are acting, or WILL act in a manner that is ILLEGAL, OPPRESSIVE, or FRAUDULENT. "Oppression" is interpreted as defeating the MINORITY SHAREHOLDER'S REASONABLE EXPECTATIONS — a flexible standard that encompasses terminating minority-shareholder employees, freezing out minority from corporate information, withholding dividends while paying excessive majority compensation, and other majority conduct that diverges from what the minority reasonably expected at formation. Leading cases: Brenner v. Berkowitz (134 N.J. 488, 1993 — establishing the reasonable-expectations framework), Muellenberg v. Bikon Corp. (143 N.J. 168, 1996 — extending fair-value buy-out as preferred remedy over dissolution), Musto v. Vidas (333 N.J. Super. 52, App. Div. 2000 — employment termination as oppression). Remedies available: ORDER OF DISSOLUTION, APPOINTMENT OF CUSTODIAN OR PROVISIONAL DIRECTOR, ORDER OF FAIR-VALUE BUY-OUT (most commonly invoked — the court determines fair value and orders the majority to purchase the minority's shares), INJUNCTIVE RELIEF. Material for closely-held NJ corps — majority cannot freely freeze out the way Delaware permits. Prophylactic measures: shareholder agreements with drag-along + buy-sell provisions at formula prices pre-empt § 14A:12-7 claims by defining the reasonable expectations.

The New Jersey Law Against Discrimination (LAD, N.J.S.A. 10:5-1 et seq) is one of the most expansive civil rights statutes in the United States. Originally enacted 1945 as the nation's second state-level anti-discrimination statute (after NY 1945), LAD covers employers with 1+ EMPLOYEES (no size threshold — federal Title VII covers 15+, most state analogs cover 4+ or 5+). LAD protected classes include: race, creed, color, national origin, ancestry, age, sex, pregnancy (including breastfeeding), gender identity and expression (added 2006 under P.L. 2006, c. 100 — FIRST US state to amend state anti-discrimination statute to include gender identity), sexual orientation (added 1991), affectional orientation, marital status, civil union status, domestic partnership status, familial status, disability, liability for military service, nationality, genetic information, and HAIRSTYLE/HAIR TEXTURE (added 2019 under the "CROWN Act," P.L. 2019, c. 272 — FIRST US state to enact hair-texture-and-style protection, landmark precedent subsequently adopted by 20+ other states). LAD damages include compensatory damages (no federal Title VII-style caps), punitive damages, attorney fees, emotional distress (NJ Supreme Court has been expansive in its interpretation). The NJ Division on Civil Rights actively enforces, plus a large + active private employment plaintiff bar makes NJ among the most litigation-active employment jurisdictions in the US. Any NJ corp with NJ-based employees must update employee handbooks, training, and HR policies to reflect LAD's full scope — over-reliance on federal-law-only policies is the #1 compliance gap.

NJ Paid Family Leave under N.J.S.A. 43:21-39.1 et seq was enacted in 2008 as the SECOND US state paid family leave program (after California 2002) and was expanded under P.L. 2019, c. 37 to provide 12 WEEKS of wage-replacement benefits (up from 6) at 85% of the employee's average weekly wage, capped at the state maximum (~$1,055/week in 2024). Funded ENTIRELY by employee payroll deduction (employer does not contribute), covering bonding with newborn/adopted/foster child, caring for seriously ill family member, or addressing domestic violence. SEPARATELY, the CORPORATE TRANSIT FEE under P.L. 2024, c. 22 (signed by Gov. Murphy June 28, 2024) is a 2.5% tax on NJ-allocated C-Corp net income ABOVE $10 MILLION, retroactive to tax years beginning on or after January 1, 2024, through December 31, 2028. Revenue is dedicated to NJ Transit — the nation's 3rd-largest public transit system — to address the ~$1 billion annual structural operating deficit created by the end of federal pandemic aid. This 2.5% stacks on top of the 9% base CBT to produce the 11.5% combined effective rate for large-cap NJ corps, the highest state corporate tax rate in the United States. The 2.5% CTF is the successor to the 2.5% CBT surtax that was retroactively extended through end of 2023 under P.L. 2023, c. 96. Planning implications: NJ's corporate tax burden on large-cap corps through 2028 is meaningfully higher than any other state, affecting domicile decisions, transfer pricing, subsidiary structuring, and state-level effective tax rate calculations for SEC reporting purposes.

The Industrial Site Recovery Act under N.J.S.A. 13:1K-6 et seq (originally the Environmental Cleanup Responsibility Act or ECRA, enacted 1983, renamed ISRA 1993) is a UNIQUE-IN-US environmental due diligence statute that triggers mandatory state-level cleanup review at corporate transaction time. ISRA is triggered by: (a) CLOSING OF OPERATIONS at an "industrial establishment," (b) TRANSFERRING OWNERSHIP of an industrial establishment (via stock sale, asset sale, merger, reorganization, or bankruptcy), or (c) SUBSTANTIALLY REDUCING operations. "Industrial establishment" is defined by Standard Industrial Classification (SIC) codes at N.J.A.C. 7:26B — broad categories including most manufacturing, chemical, pharmaceutical, printing, hospital/laboratory operations. Triggered transactions require: (1) filing a General Information Notice + Preliminary Assessment with NJ Department of Environmental Protection (NJDEP), (2) conducting Site Investigation to evaluate contamination, (3) Remedial Action if contamination is found, (4) issuance of a No Further Action (NFA) letter or Response Action Outcome (RAO) by a Licensed Site Remediation Professional (LSRP). Material for any corporate M&A transaction involving NJ-located industrial operations — environmental due diligence costs routinely range $50K–$500K per transaction, and cleanup liabilities can reach multi-million dollars or more for contaminated legacy sites (particularly pharma, specialty chemicals, electroplating, dry cleaning). Cannot close a transaction without ISRA compliance or NJDEP clearance. Reformed 2009 under the Site Remediation Reform Act which privatized the LSRP model — but the underlying ISRA trigger structure remains in force. Critical factor in NJ pharma/manufacturing transaction cost and timeline — most corporate counsel plan for 90–180 days of ISRA diligence on NJ industrial acquisitions.

The NJ Annual Report is due by the LAST DAY of your corporation's anniversary month under N.J.S.A. 14A:4-6 — not a flat calendar deadline. Fee is $78 filed online via the DORES portal at business.nj.gov. Late filing triggers a $75 late fee. Failure to file for TWO consecutive years triggers ADMINISTRATIVE REVOCATION of corporate good standing under N.J.S.A. 14A:4-5 — the corporation is not dissolved, but it loses its Certificate of Good Standing, which cascades into: bank accounts frozen (banks require annual Certificate of Good Standing renewals), inability to maintain or defend lawsuits in NJ courts, contract counterparties exercising termination rights, inability to qualify to transact business in other states (states require home-state good standing for foreign qualification), loss of right to use the corporate name (a new corp can register the same name after 12 months of revocation). Reinstatement requires filing all missed Annual Reports + cumulative $75 late fees + $95 reinstatement fee + Certificate of Reinstatement + proof of tax compliance (Tax Clearance Certificate from Division of Taxation). Reinstatement is typically granted within 30 days if all filings are current. However, revocation does not dissolve the underlying entity, which means: (a) any NJ CBT liability continues to accrue during revocation, (b) officers/directors can be held PERSONALLY LIABLE for contractual obligations incurred during revocation under N.J.S.A. 14A:12-2 (since the corporation lacks capacity to contract when revoked). Calendar the Annual Report as a zero-tolerance compliance item.

New Jersey historically did NOT automatically honor federal S-Corp elections — NJ required a separate state-level election via Form CBT-2553 filed with the Division of Taxation under N.J.S.A. 54:10A-5.22. This is a NATIONWIDE OUTLIER (most states automatically honor federal S-elections). In 2022, NJ streamlined the process via P.L. 2022, c. 133 which ELIMINATED the separate NJ S-election requirement effective for tax years beginning on or after January 1, 2022 — NJ now automatically treats federally-elected S-Corps as NJ S-Corps unless the entity affirmatively opts out via Form CBT-2553-R. S-Corps are still subject to the MINIMUM CBT ($500–$2,000 sliding scale) but pass through operating income to shareholders for personal NJ Gross Income Tax (GIT) purposes at graduated rates up to 10.75% under N.J.S.A. 54A:2-1 (the 10.75% tier applies to individual income above $1M — one of highest US state personal income tax rates after CA 13.3% and HI 11%). NJ LLCs are taxed as partnerships by default under N.J.S.A. 42:2C-9, with a per-member partnership fee under N.J.S.A. 54:10A-15.11 ($150 per member up to $250K cap). New S-Corps forming in 2022+ do NOT need to file the separate NJ election — file federal Form 2553 with IRS and you're automatically a NJ S-Corp. LLCs electing federal S-Corp treatment (LLC + Form 2553) are treated consistent with the federal election for NJ purposes.

Port Newark-Elizabeth Marine Terminal (operated by Port Authority of New York and New Jersey — PANYNJ) is the 3rd-busiest US container port behind Los Angeles and Long Beach, handling approximately 7.8 MILLION TEUs annually — the primary East Coast transatlantic gateway. Combined with Newark Liberty International Airport (United's 3rd-largest hub, ~50M passengers, #11 US cargo airport), the NJ import/export gateway handles the majority of East Coast intercontinental freight. Corp formation implications: NJ Division of Consumer Affairs motor carrier registration required for NJ intrastate carriers, federal FMCSA for interstate, NJ Motor Vehicle Commission Gross Vehicle Weight + Commercial Driver License programs, PANYNJ ExpressRail / ocean terminal operator agreements for port drayage, customs broker licensing for import/export operations. Jersey City / Hudson waterfront is NJ's second major corporate cluster — the primary Manhattan financial back-office market hosting Goldman Sachs 30 Hudson Street (~8K employees), JPMorgan Chase operations, Merrill Lynch/Bank of America Hopewell + Jersey City, UBS Weehawken, and DEPOSITORY TRUST & CLEARING CORPORATION (DTCC) Jersey City — the world's largest post-trade financial services infrastructure with ~$2.5 QUADRILLION in annual settled transaction volume. The Exchange Place + Harborside Financial Center + Newport waterfront hosts approximately 250,000 financial services employees. For corps operating in either cluster: NJ CBT nexus is triggered by maintaining offices in NJ (even for non-NJ-customer operations); most back-office operating corps are DE-incorporated and foreign-qualified to NJ; NJ's single-sales-factor apportionment under N.J.S.A. 54:10A-6 means NJ CBT is computed on the fraction of company-wide sales sourced to NJ, which for services uses cost-of-performance — creating planning opportunities (or traps) depending on where services are actually performed.

NJ TURNPIKE AUTHORITY under N.J.S.A. 27:23-1 et seq operates the NJ Turnpike (widely recognized as the #1 US toll-revenue highway at ~$2.1 billion annually) plus the Garden State Parkway — material for NJ-domiciled transportation, logistics, trucking, and auto-services corps given the unusual prominence of toll infrastructure in NJ commerce. ATLANTIC CITY CASINOS under the NJ Casino Control Act, N.J.S.A. 5:12-1 et seq, are licensed by the NJ Casino Control Commission + Division of Gaming Enforcement — 9 operating casinos post-2014 closures, governed by some of the strictest anti-money-laundering + responsible-gaming standards in the US. NJ sports betting went live in June 2018 following the landmark US Supreme Court decision in MURPHY v. NCAA (138 S. Ct. 1461, 2018), in which NJ successfully challenged the federal Professional and Amateur Sports Protection Act (PASPA) as unconstitutional commandeering of state regulatory authority under the Tenth Amendment. This single NJ litigation persistence triggered the national sports-betting legalization wave — 38 states now have some form of legal sports betting. NJ sports wagering handle is approximately $12B annually (behind NY and NV), generating ~$85M state revenue via 8.5% retail + 13% online gross revenue tax. Top operators: FanDuel (operating Meadowlands retail), DraftKings (Flutter Entertainment's Irish parent), BetMGM / Resorts / Caesars Interactive. NJ cannabis was legalized for adult-use recreational February 2021 under P.L. 2021, c. 16 (the CREAMM Act — Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act). NJ Cannabis Regulatory Commission (CRC) licenses cultivators, manufacturers, wholesalers, distributors, retailers, and delivery services. Taxation: 6.625% state sales tax + optional local cannabis transfer tax up to 2%. NJ cannabis market remains significantly smaller than CA/CO/MI/MA due to regulatory rollout pace + constrained license count.

Form elsewhere if any of these apply. (1) VC-BOUND STARTUPS: Most NJ + NY-area VCs still expect DGCL term sheets for priced-equity rounds — the NVCA Model Term Sheet + YC SAFE + Series Seed templates assume Delaware. NJ's § 14A is NOT MBCA-aligned and its § 14A:12-7 shareholder oppression jurisprudence protects minority holders in a way that cuts against typical VC-backed founder-majority flexibility. Form DE day one and foreign-qualify into NJ at $125 + $78/yr + $500 min CBT = $703/year carrying cost. (2) ANONYMOUS HOLDING COMPANIES: NJ Certificate of Incorporation requires registered office + named registered agent + incorporator on public record. Form Wyoming (W.S. § 17-29-201 anonymous + $60/yr license tax) or New Mexico ($50 filing + $0 annual report + anonymous allowed). (3) PURE NO-INCOME-TAX SEEKERS: NJ's 11.5% combined effective rate for large corps (>$10M net income through 2028) is the highest in the US. Go WY / NV / SD / TX / FL / WA for zero state corp income tax. (4) PRE-REVENUE EXTREME COST OPTIMIZERS: NJ's $125 formation + $78 annual + $500 minimum CBT = $703/year is among the highest US carrying costs. Mississippi is $50 form + $25 annual = $75/year. New Mexico is $50 lifetime (no annual fee). Delaware is $109 form + $50 annual + $175 minimum franchise tax = $334/year for non-operating corp. (5) LARGE-AUTHORIZED-SHARE PRICED-EQUITY CORPS: NJ's flat $125 filing is favorable here (unlike MI's $14,970 for 10M shares or VA's $22,525 max), but DGCL's assumed-par-value franchise tax method typically beats NJ annual report + minimum CBT once income scales. NJ IS the right answer when: (a) substantial NJ operations — pharma corridor, Port Newark, Jersey City finance — AND (b) corp will not seek institutional equity (non-VC-track), AND (c) closely-held / family-business / founder-employee structure where § 14A:12-7 minority protection is actually desired.